Related Experiment Video
Updated: Jun 27, 2026
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
[DDP-sensitivity-related genes in 10 lung cancer cell lines]
Chun-hong Li1, Li Cai, Xue-song Chen
1Internal Medicine Department, Third Affiliated Hospital, Harbin Medical University, China.
Objective:
To search for genes related to cisplatin (DDP) sensitivity in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) cell lines.
Methods:
The sensitivity of 4 SCLC lines and 6 NSCLC lines to DDP was evaluated by MTT assay. The expression of 1291 genes related to DDP-sensitivity in the 10 cell lines was measured by cDNA macroarray and the relationship between genes and DDP-sensitivity was analyzed.
Results:
20 genes were negatively related to DDP-sensitivity in the SCLC and NSCLC cell lines, including Metallothionein, Cathepsin B, TIMP1, TNF-R1, TGF beta-induced 68 000, Cathepsin L, Galectin-1, Annexin 11, PAI-1, IGFBP4, UPAR, Jagged, CD13, alpha 1 A-AR, EphA2 (Eck), APC, RhoC, Fibromodulin, GATA-6 and HSC 70, while only procoagula and MDM2 were positively related to DDP-sensitivity in the SCLC and NSCLC cell lines. 10 genes were negatively related to DDP-sensitivity in the SCLC cell lines, including VHL, MMP-7, Elongin A, GSK-3 beta, SLC, Galectin-3, integrin beta 5, moesin, IKK beta, and ETV 1, while only AT2 was positively related to DDP-sensitivity in the SCLC cell lines. 10 genes were negatively related to DDP-sensitivity in the NSCLC cell lines, including Clusterin, FG FR-2, Thrombospondin 1, HSP 32, Lactate dehydrogenase A, P300, Thymosin beta l0, CD81, C/EBP gamma, Rak, while only CaMKK and TPA were positively related to DDP-sensitivity in the NSCLC cell lines.
Conclusion:
There were 45 genes related to DDP-sensitivity in 10 lung cancer cell lines. There were 22 co-expressed genes in both SCLC and NSCLC cell lines, and only 11 and 12 genes expressed in the SCLC and NSCLC cell lines, respectively.
Insights
This study identified 45 genes associated with cisplatin sensitivity in lung cancer cell lines. Key genes were found to be co-expressed in both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) subtypes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Cisplatin (DDP) is a cornerstone chemotherapy agent for both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).
- Understanding the genetic basis of DDP sensitivity is crucial for optimizing treatment strategies and improving patient outcomes.
- Lung cancer remains a leading cause of cancer-related mortality worldwide, necessitating novel therapeutic targets and biomarkers.
Purpose:
- To identify and analyze genes correlated with cisplatin (DDP) sensitivity in SCLC and NSCLC cell lines.
- To investigate the differential gene expression patterns related to DDP sensitivity between SCLC and NSCLC.
- To discover potential genetic biomarkers for predicting DDP response in lung cancer.
Summary:
- A total of 1291 genes were analyzed for their association with DDP sensitivity across 4 SCLC and 6 NSCLC cell lines using MTT assays and cDNA macroarrays.
- The study identified 45 genes related to DDP sensitivity, with 22 genes showing co-expression in both SCLC and NSCLC. Specific sets of 11 and 12 genes were uniquely associated with SCLC and NSCLC, respectively.
- Several genes, including Metallothionein, Cathepsin B, and Galectin-1, were found to be negatively related to DDP sensitivity in both cancer types, while others like procoagula and MDM2 were positively associated.
Impact:
- This research provides a comprehensive list of candidate genes that could serve as biomarkers for DDP sensitivity in lung cancer.
- The findings may facilitate the development of targeted therapies or combination treatments to overcome cisplatin resistance.
- Identifying co-expressed genes offers insights into common mechanisms of DDP response and resistance across different lung cancer subtypes.